- Conditions
- Type 1 Diabetes Mellitus, Maturity-Onset Diabetes of the Young, Type 2, MODY2, Insulin Resistance
- Interventions
- Hyperinsulinemic, euglycemic clamp, 20% dextrose
- Drug
- Lead sponsor
- Vanderbilt University
- Other
- Eligibility
- 13 Years to 51 Years
- Enrollment
- 33 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2016 – 2019
- U.S. locations
- 1
- States / cities
- Nashville, Tennessee
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 25–48
of 24
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Obesity
- Interventions
- Liraglutide, Placebo
- Drug
- Lead sponsor
- Michael Camilleri, MD
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 136 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2017 – 2021
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota
- Conditions
- CABG
- Interventions
- Placebo, GLP-1 (7-36) amide
- Drug
- Lead sponsor
- Johns Hopkins University
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2012
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Type 1 Diabetes Mellitus
- Interventions
- REMD-477
- Drug
- Lead sponsor
- University of California, San Diego
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 4 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2022
- U.S. locations
- 1
- States / cities
- La Jolla, California
- Conditions
- Obesity
- Interventions
- Phentermine Pill, Orforglipron
- Drug
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2031
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Pre-diabetes, Type 2 Diabetes
- Interventions
- Exenatide, Sitagliptin, Glimepiride
- Drug
- Lead sponsor
- University of Pennsylvania
- Other
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 47 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2012
- U.S. locations
- 3
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Type 1 Diabetes Mellitus
- Interventions
- The Fading Memory Proportional Derivative/Adaptive Proportional Derivative Algorithm, The Adaptive Proportional Derivative Algorithm
- Device
- Lead sponsor
- Legacy Health System
- Other
- Eligibility
- 21 Years to 65 Years
- Enrollment
- 14 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2010 – 2011
- U.S. locations
- 1
- States / cities
- Portland, Oregon
- Conditions
- Type 2 Diabetes, Comparative Effectiveness of Glycemia-lowering Medications
- Interventions
- Sulfonylurea (glimepiride), DPP-4 inhibitor (sitagliptin), GLP-1 receptor agonist (liraglutide), Insulin (glargine)
- Drug
- Lead sponsor
- GRADE Study Group
- Other
- Eligibility
- 30 Years and older
- Enrollment
- 7,850 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2021
- U.S. locations
- 36
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • San Diego, California + 28 more
- Conditions
- Hypoglycemia
- Interventions
- Glucagon for Injection (Fresenius Kabi USA), Glucagon for Injection (Bedford Laboratories)
- Drug
- Lead sponsor
- Fresenius Kabi USA, LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 32 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2013
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- Semaglutide, Placebos
- Drug
- Lead sponsor
- Sabyasachi Sen
- Other
- Eligibility
- 20 Years to 90 Years
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2025
- U.S. locations
- 2
- States / cities
- Washington D.C., District of Columbia
- Conditions
- Obesity, Diabetes, Roux-en-Y Gastric Bypass
- Interventions
- Exendin-9,39, Saline
- Drug · Other
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 20 Years to 70 Years
- Enrollment
- 3 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2019
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota
- Conditions
- Healthy, Type 2 Diabetes, Obesity
- Interventions
- Dextrose, Clinisol 15%
- Drug
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 25 Years to 65 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023 – 2026
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota
- Conditions
- Type 2 Diabetes
- Interventions
- Liraglutide, Metformin
- Drug
- Lead sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
- NIH
- Eligibility
- 12 Years to 25 Years
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2022
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Obesity
- Interventions
- Incretin-based therapies (GLP-1 and GLP-1/GIP)
- Drug
- Lead sponsor
- Indiana University
- Other
- Eligibility
- 18 Years to 64 Years
- Enrollment
- 125,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2029
- U.S. locations
- 1
- States / cities
- Indianapolis, Indiana
- Conditions
- Type 2 Diabetes
- Interventions
- Tirzepatide, Dulaglutide, Semaglutide
- Drug
- Lead sponsor
- Brigham and Women's Hospital
- Other
- Eligibility
- 40 Years and older
- Enrollment
- 70,000 participants
- Timeline
- 2024 – 2026
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Diabetes Mellitus, Type 1, Diabetes, Type 1 Diabetes, Diabetes Mellitus
- Interventions
- No intervention
- Other
- Lead sponsor
- T1D Exchange, United States
- Other
- Eligibility
- Not listed
- Enrollment
- 50,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2030
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Obesity/Therapy
- Interventions
- Semaglutide 1.7mg subcutaneous, Placebo
- Drug
- Lead sponsor
- University of Colorado, Denver
- Other
- Eligibility
- 12 Years to 45 Years
- Enrollment
- 120 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2031
- U.S. locations
- 1
- States / cities
- Aurora, Colorado
- Conditions
- Normal Cellular Metabolism
- Interventions
- Somatostatin, Glucagon
- Drug
- Lead sponsor
- K. Sreekumaran Nair
- Other
- Eligibility
- 18 Years to 45 Years
- Enrollment
- 17 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2016 – 2017
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota
- Conditions
- Overweight or Obesity
- Interventions
- TERN-601, Matching Placebo
- Drug · Other
- Lead sponsor
- Terns, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 167 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025
- U.S. locations
- 17
- States / cities
- Birmingham, Alabama • Homewood, Alabama • Tucson, Arizona + 14 more
- Conditions
- Diabetes Mellitus, Type 2 Diabetes
- Interventions
- Diabetes Staging System (DSS) use among Primary Care Teams
- Other
- Lead sponsor
- Durham VA Medical Center
- Federal
- Eligibility
- 25 Years to 75 Years
- Enrollment
- 120 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023 – 2025
- U.S. locations
- 1
- States / cities
- Greenville, North Carolina
- Conditions
- Gastric Bypass Surgery, Gastric Banding, Type 2 Diabetes
- Interventions
- Not listed
- Lead sponsor
- St. Luke's-Roosevelt Hospital Center
- Other
- Eligibility
- 20 Years to 60 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2014
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Obesity
- Interventions
- Not listed
- Lead sponsor
- University of Minnesota
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 12 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2011 – 2013
- U.S. locations
- 1
- States / cities
- Minneapolis, Minnesota
- Conditions
- Hyperglycemia Drug Induced
- Interventions
- REMD-477
- Biological
- Lead sponsor
- Duke University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 1 participant
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2021
- U.S. locations
- 1
- States / cities
- Durham, North Carolina
- Conditions
- Healthy
- Interventions
- Bimagrumab, Tirzepatide, Bimagrumab + Tirzepatide Coformulation
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years to 64 Years
- Enrollment
- 125 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025
- U.S. locations
- 1
- States / cities
- Dallas, Texas